Lineage Cell Therapeutics Inc (LCTX)

1.600
+0.040(+2.56%)
  • Volume:
    119,235
  • Day's Range:
    1.560 - 1.640
  • 52 wk Range:
    1.100 - 2.800
Earnings results expected today

LCTX Overview

Prev. Close
1.56
Day's Range
1.56-1.64
Revenue
9.19M
Open
1.57
52 wk Range
1.1-2.8
EPS
-0.29
Volume
119,235
Market Cap
271.56M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
902,887
P/E Ratio
-
Beta
1.62
1-Year Change
-39.69%
Shares Outstanding
169,727,395
Next Earnings Date
Aug 11, 2022
What is your sentiment on Lineage Cell Therapeutics?
or
Vote to see community's results!

Lineage Cell Therapeutics Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade
  • AMD, BA, VALE among premarket gainers
    • BySeeking Alpha-

    Co-Diagnostics (NASDAQ:CODX) +176% on eliminating debt.Eyenovia (NASDAQ:EYEN) +52% on positive MicroStat data.Ekso Bionics Holdings (NASDAQ:EKSO) +33% on $100M JV to develop the...

Lineage Cell Therapeutics Inc Analysis

Lineage Cell Therapeutics Inc Company Profile

Lineage Cell Therapeutics Inc Company Profile

Employees
52

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing cell therapies to address unmet medical needs. The Company designs, develops, and manufactures specialized human cells with anatomical and physiological functions which are similar or identical to cells found naturally in the human body. It has three allogeneic product candidates: OpRegen, OPC1 and VAC2. OpRegen is a retinal pigment epithelium (RPE) cell replacement therapy, which is in a Phase I/IIa multicenter clinical trial for the treatment of advanced dry age-related macular degeneration (AMD) with geographic atrophy (GA). OPC1 is an oligodendrocyte progenitor cell therapy, which is in a follow-up for a Phase I/IIa multicenter clinical trial for spinal cord injuries (SCI). VAC is an allogeneic cancer immunotherapy of antigen-presenting dendritic cells. Its VAC product candidates include, VAC2, which is in a Phase I clinical trial in non-small cell lung cancer (NSCLC).

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuyBuyNeutralSell
Technical IndicatorsSellStrong BuyStrong BuySellStrong Sell
SummaryNeutralStrong BuyStrong BuyNeutralStrong Sell
  • LCTX is gonna skyrocket in a few month from now, and it's gonna be parabolic 10x
    1
    • We waited 100 days and went back to 3 usd
      0
      • and? Are you holding or selling? What is your pt?
        0
    • why nobody comments this good result?
      0
      • i wait for 5 usd. until 2022
        0
        • dont wait for 3 usd
          1
          • we need another spike to 3$
            0
            • Hello any news from your side?
              0
          • after 7 dsys of declines it is clear ee have been captured by a digital organization of bad people
            0
            • Why is this?
              0
          • I can’t find something that will help me understand what was the reason she started to fly
            0
            • because it is a good stock to hold long and strong
              0
          • why is it down
            2
            • there does not seem to be a justifiable reason other than the difficulty of getting on without taking air on the way.let's hope for the best
              0
            • difficulty of getting on without taking air on the way.
              0
          • We are really close to $3 but then¿ I seethe avg target price is $5.25 and the highest $7...any thoughts?
            0